ASIT biotech Continues Its Transformation From Research to Late Stage Clinical Development
Company shareholders approve all motions at Extraordinary General Meeting Firm expects to raise €9-12 M to finance focused development Jean-Paul Prieels confirmed as new member of Board of Directo...
More From BioPortfolio on "ASIT biotech Continues Its Transformation From Research to Late Stage Clinical Development"